LTGO (Latigo Biotherapeutics) Issuance of Debt: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTGO Latigo Biotherapeutics Inc LTGO
8 GF Score
Price $18.14
View Full Analysis

What is Latigo Biotherapeutics Issuance of Debt?

Latigo Biotherapeutics LTGO -0.60% 8 Issuance of Debt is $0.00 Mil as of Dec. 2025. GuruFocus rates LTGO with a GF Score™ of 8/100.

Latigo Biotherapeutics's Issuance of Debt for the six months ended in Dec. 2025 was $0.00 Mil.

Latigo Biotherapeutics's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

Latigo Biotherapeutics Issuance of Debt Related Terms

Latigo Biotherapeutics Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Latigo Biotherapeutics's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Latigo Biotherapeutics Issuance of Debt Chart

Latigo Biotherapeutics Annual Data
Trend Dec24 Dec25
Issuance of Debt
0.00 0.00

Latigo Biotherapeutics Semi-Annual Data
Dec24 Dec25
Issuance of Debt 0.00 0.00
LTGO
8GF Score
Latigo Biotherapeutics Inc LTGO
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Latigo Biotherapeutics Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $0.00 Mil mean?
Latigo Biotherapeutics (LTGO) has a Issuance of Debt of $0.00 Mil as of Dec. 2025. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Latigo Biotherapeutics and its competitors.
Is Latigo Biotherapeutics' Issuance of Debt too high?
Latigo Biotherapeutics' current Issuance of Debt is $0.00 Mil. Overall, Latigo Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Latigo Biotherapeutics' Issuance of Debt compare to ?
Latigo Biotherapeutics' Issuance of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Latigo Biotherapeutics and its competitors. Latigo Biotherapeutics's current Issuance of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Latigo Biotherapeutics stock overvalued right now?
Latigo Biotherapeutics (LTGO) has a current Issuance of Debt of $0.00 Mil. The current Issuance of Debt is $0.00 Mil. Latigo Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Latigo Biotherapeutics (LTGO), the current Issuance of Debt is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Latigo Biotherapeutics Business Description

Comparable Companies
Address 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA, USA, 91320
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
8GF Score

Get the complete analysis for LTGO

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.14
Price